"uuid:ID","name","id","text","sectionTitle","sectionNumber"
"dbfbe0d9-9f66-4c31-bf63-5b465911cdde","ROOT","NarrativeContent_1","","Root","0"
"5aeb601c-b7b4-4365-a44d-f5119eefc079","SECTION 1","NarrativeContent_2","<div><usdm:ref klass=""StudyIdentifier"" id=""StudyIdentifier_1"" attribute=""studyIdentifier""/></div>","PROTOCOL SUMMARY","1"
"02c34dec-c2fd-4d6b-b100-b025fa5c9de5","SECTION 1.1","NarrativeContent_3","<div></div>","Protocol Synopsis","1.1"
"baefc4fc-f68d-4674-84ee-4971978b787f","SECTION 1.2","NarrativeContent_4","<div></div>","Trial Schema","1.2"
"06b2f670-b508-43eb-8233-b5664abdb116","SECTION 1.3","NarrativeContent_5","<div></div>","Schedule of Activities","1.3"
"7e944917-024c-475d-8d68-7d2a9eef97dc","SECTION 2","NarrativeContent_6","<div></div>","INTRODUCTION","2"
"f9103e73-afca-4820-a06e-8f775e6509e5","SECTION 2.1","NarrativeContent_7","<div></div>","Purpose of Trial","2.1"
"c3eba82e-c1fb-438a-b81a-e93db9511231","SECTION 2.2","NarrativeContent_8","<div></div>","Summary of Benefits and Risks","2.2"
"73f85fab-13dd-41ce-b284-606d93d734b1","SECTION 3","NarrativeContent_9","<div></div>","TRIAL OBJECTIVES, ENDPOINTS AND ESTIMANDS","3"
"31e71cdf-4891-4ee9-98d9-8a5a6ddf2500","SECTION 3.1","NarrativeContent_10","<div><table>
  <tr>
    <th style=""vertical-align: top"">Primary Objective</th>
    <th style=""vertical-align: top"">Primary Endpoint</th>
  </tr>
  <tr>
    <td style=""vertical-align: top""><usdm:ref klass=""Objective"" namexref=""OBJ1"" attribute=""description""/></td>
    <td style=""vertical-align: top""><usdm:ref klass=""Endpoint"" id=""Endpoint_1"" attribute=""description""/></td>
  </tr>
</table></div>","Primary Objectives","3.1"
"4d34ec47-e5cb-4769-90b3-6d41ccc81d8a","SECTION 4","NarrativeContent_11","<div></div>","TRIAL DESIGN","4"
"693ca570-833b-4886-a59d-3fd8f1962d44","SECTION 4.1","NarrativeContent_12","<div></div>","Description of Trial Design","4.1"
"d339f05d-4654-4e9a-a126-045f5a192f93","SECTION 4.1.1","NarrativeContent_13","<div></div>","Participant Input into Design","4.1.1"
"9039e53b-fc87-4898-9a8a-1b5e56ab8515","SECTION 4.2","NarrativeContent_14","<div></div>","Rationale for Trial Design","4.2"
"9f0214df-2a22-4fe2-99c2-cd3bad914cb2","SECTION 4.2.1","NarrativeContent_15","<div></div>","Rationale for Comparator","4.2.1"
"47a4c727-8736-4f2c-85db-3ada323704fd","SECTION 4.2.2","NarrativeContent_16","<div></div>","Rationale for Adaptive or Novel Trial Design","4.2.2"
"0ffa9221-d637-4448-9759-ef19bab7c5d4","SECTION 4.2.3","NarrativeContent_17","<div></div>","Other Trial Design Considerations","4.2.3"
"bead259c-1bae-48fd-872a-eb7a23f0773a","SECTION 4.3","NarrativeContent_18","<div></div>","Access to Trial Intervention After End of Trial","4.3"
"d0e4fd8b-49bc-41c6-ac9a-9e816ab9f0a5","SECTION 4.4","NarrativeContent_19","<div></div>","Start of Trial and End of Trial","4.4"
"708f770a-86be-4925-b44f-b6735f3d6736","SECTION 5","NarrativeContent_20","<div></div>","TRIAL POPULATION","5"
"6c1bac9a-689f-4566-a4e6-91800936daf2","SECTION 5.1","NarrativeContent_21","<div></div>","Selection of Trial Population","5.1"
"abe358cf-0a4e-44e3-919e-28bf24f7fd47","SECTION 5.2","NarrativeContent_22","<div></div>","Rationale for Trial Population","5.2"
"1d88c217-0984-4536-82a5-6626c33e6210","SECTION 5.3","NarrativeContent_23","<div><p>Inclusion criteria are:</p>
<ul>
  <li>1. Something</li>
  <li>2. Something else</li>
</ul></div>","Inclusion Criteria","5.3"
"fef7ef40-3e43-4d4c-8bf7-18a5ffb11bcf","SECTION 5.4","NarrativeContent_24","<div><p>Exclusion criteria are:</p>
<ul>
  <li>1. Dont do this</li>
  <li>2. And don't do that</li>
</ul></div>","Exclusion Criteria","5.4"
"42f6f3cc-6324-483f-82eb-ec2fcc8b51fd","SECTION 5.5","NarrativeContent_25","<div></div>","Lifestyle Considerations","5.5"
"c796ead3-7020-4542-ae05-53bfdab2aa0a","SECTION 5.5.1","NarrativeContent_26","<div></div>","Meals and Dietary Restrictions","5.5.1"
"143487bd-d471-421b-a8bc-a195e33c3675","SECTION 5.5.2","NarrativeContent_27","<div></div>","Caffeine, Alcohol, Tobacco, and Other Habits","5.5.2"
"d3427921-5872-4ce8-9764-73d6583ed2c3","SECTION 5.5.3","NarrativeContent_28","<div></div>","Physical Activity","5.5.3"
"1cba592b-3312-4689-979b-a17b48a8f334","SECTION 5.5.4","NarrativeContent_29","<div></div>","Other Activity","5.5.4"
"53f8686e-e707-4c1b-a95f-2525bf365620","SECTION 5.6","NarrativeContent_30","<div></div>","Screen Failures","5.6"
"796cf01d-e1b6-4c7a-8831-d0e58a15dc75","SECTION 6","NarrativeContent_31","<div></div>","TRIAL INTERVENTION AND CONCOMITANT THERAPY","6"
"0c76ab96-8f3c-4c78-a1d0-16d2db0b9342","SECTION 6.1","NarrativeContent_32","<div></div>","Description of Trial Intervention","6.1"
"86d8bfbc-3d38-470d-ac41-8839f6950d78","SECTION 6.2","NarrativeContent_33","<div></div>","Rationale for Trial Intervention","6.2"
"f8266813-fbf1-4a5a-b0e2-104b4e16b92b","SECTION 6.3","NarrativeContent_34","<div></div>","Dosing and Administration","6.3"
"f13d6be4-37b7-48cf-86e9-7755d7b3d44d","SECTION 6.3.1","NarrativeContent_35","<div></div>","Trial Intervention Dose Modification","6.3.1"
"77d0660f-c4ed-4299-91fe-4717037d8af9","SECTION 6.4","NarrativeContent_36","<div></div>","Treatment of Overdose","6.4"
"3fbcec80-7eae-453c-83fe-f93900d0a664","SECTION 6.5","NarrativeContent_37","<div></div>","Preparation, Handling, Storage and Accountability","6.5"
"e5b20766-c420-4958-aa64-497f97f04832","SECTION 6.5.1","NarrativeContent_38","<div></div>","Preparation of Trial Intervention","6.5.1"
"ce47c77f-20a7-4dad-bd41-eff09d344d2d","SECTION 6.5.2","NarrativeContent_39","<div></div>","Handling and Storage of Trial Intervention","6.5.2"
"c8a83896-282e-49e7-8f6c-d4c97f347e49","SECTION 6.5.3","NarrativeContent_40","<div></div>","Accountability of Trial Intervention","6.5.3"
"48540d5d-4fe1-4b89-a05d-da8b957afa0b","SECTION 6.6","NarrativeContent_41","<div></div>","Participant Assignment, Randomisation and Blinding","6.6"
"aa1e5a38-7db5-4c73-9586-0de57a5db7d7","SECTION 6.6.1","NarrativeContent_42","<div></div>","Participant Assignment","6.6.1"
"532d17a8-b5ab-4150-89d0-4c43c013ff71","SECTION 6.6.2","NarrativeContent_43","<div></div>","Randomisation","6.6.2"
"056bdd8b-8fa6-4bc1-8f03-7bcd9f26ce42","SECTION 6.6.3","NarrativeContent_44","<div><p>Blinding and unblinding text here please</p></div>","Blinding and Unblinding","6.6.3"
"c7faac97-f920-463f-aa79-d99f3540cfd7","SECTION 6.7","NarrativeContent_45","<div></div>","Trial Intervention Compliance","6.7"
"026e17d8-b2a2-4e51-95ee-9f85dbdb8887","SECTION 6.8","NarrativeContent_46","<div></div>","Concomitant Therapy","6.8"
"33a881df-3152-4673-9eb0-18dcf572fdc3","SECTION 6.8.1","NarrativeContent_47","<div></div>","Prohibited Concomitant Therapy","6.8.1"
"fc38c422-6cea-457f-ac17-8ce3aaaa30c3","SECTION 6.8.2","NarrativeContent_48","<div></div>","Permitted Concomitant Therapy","6.8.2"
"682d867c-cc00-4c51-a535-6a96a1fa1f5d","SECTION 6.8.3","NarrativeContent_49","<div></div>","Rescue Therapy","6.8.3"
"3750b5eb-bbe2-49f3-8b05-3a17a1b2a67b","SECTION 6.8.4","NarrativeContent_50","<div></div>","Other Therapy","6.8.4"
"6856d5b3-7f93-4c46-9c2a-7d60578c6d68","SECTION 7","NarrativeContent_51","<div></div>","DISCONTINUATION OF TRIAL INTERVENTION AND PARTICIPANT WITHDRAWAL FROM TRIAL","7"
"0444262e-d293-4d20-a3ec-d532f741a4c7","SECTION 7.1","NarrativeContent_52","<div></div>","Discontinuation of Trial Intervention","7.1"
"84bacdb7-51d6-43d8-acfd-af5341758b3d","SECTION 7.1.1","NarrativeContent_53","<div></div>","Criteria for Permanent Discontinuation of Trial Intervention","7.1.1"
"c1d22547-92d4-4c24-a73c-775e23216205","SECTION 7.1.2","NarrativeContent_54","<div></div>","Temporary Discontinuation or Interruption of Trial Intervention","7.1.2"
"40de8cf4-5045-43d3-8e3a-cc41c13d65d2","SECTION 7.1.3","NarrativeContent_55","<div></div>","Rechallenge","7.1.3"
"2df10b05-5f45-4088-b2b8-5989f03865a1","SECTION 7.2","NarrativeContent_56","<div></div>","Participant Withdrawal from the Trial","7.2"
"9cd186af-cdf9-44ca-96fd-607376ef0e9c","SECTION 7.3","NarrativeContent_57","<div></div>","Lost to Follow-Up","7.3"
"6ce2e6f5-04a9-45a2-94e4-f59fed93add4","SECTION 7.4","NarrativeContent_58","<div></div>","Trial Stopping Rules","7.4"
"3cb1c553-5de8-47b2-b6e3-5afbb0b336aa","SECTION 8","NarrativeContent_59","<div></div>","TRIAL ASSESSMENTS AND PROCEDURES","8"
"e518383b-659d-4efe-9cde-717255118bdd","SECTION 8.1","NarrativeContent_60","<div></div>","Screening/Baseline Assessments and Procedures","8.1"
"99ec79c2-7888-4c35-92f3-6a3451797cfb","SECTION 8.2","NarrativeContent_61","<div></div>","Efficacy Assessments and Procedures","8.2"
"7d9ddee6-9e7d-41c2-9c72-7fed82eb0e93","SECTION 8.3","NarrativeContent_62","<div></div>","Safety Assessments and Procedures","8.3"
"a099b9a1-79ee-4062-b90f-0cb82a3027e1","SECTION 8.3.1","NarrativeContent_63","<div></div>","Physical Examination","8.3.1"
"558f3f84-527d-46b7-99d6-c385d3a51d76","SECTION 8.3.2","NarrativeContent_64","<div></div>","Vital Signs","8.3.2"
"524f9757-1716-40ad-ba77-bb3fa1c3565a","SECTION 8.3.3","NarrativeContent_65","<div></div>","Electrocardiograms","8.3.3"
"23a29efa-0262-4cdb-8695-a93e94eb323c","SECTION 8.3.4","NarrativeContent_66","<div></div>","Clinical Laboratory Assessments","8.3.4"
"a9e9f5ef-5efd-40b7-8394-fc8cb96756d8","SECTION 8.3.5","NarrativeContent_67","<div></div>","Suicidal Ideation and Behaviour Risk Monitoring","8.3.5"
"13abf382-1d6e-4270-8f7e-08a46ca5c19c","SECTION 8.4","NarrativeContent_68","<div></div>","Adverse Events and Serious Adverse Events","8.4"
"d862470e-179e-4a48-9121-d462435f18a4","SECTION 8.4.1","NarrativeContent_69","<div></div>","Definitions of AE and SAE","8.4.1"
"46253a7b-a83b-4126-a1ff-d3aee547a894","SECTION 8.4.2","NarrativeContent_70","<div></div>","Time Period and Frequency for Collecting AE and SAE Information","8.4.2"
"d085528d-8d99-41be-96f9-b4ff0fd46630","SECTION 8.4.3","NarrativeContent_71","<div></div>","Identifying AEs and SAEs","8.4.3"
"592551ce-3ed2-49a7-b689-82b919d5b8c7","SECTION 8.4.4","NarrativeContent_72","<div></div>","Recording of AEs and SAEs","8.4.4"
"e0275cef-86aa-4554-88fa-dd0dcb48552a","SECTION 8.4.5","NarrativeContent_73","<div></div>","Follow-up of AEs and SAEs","8.4.5"
"a45738d3-ad1c-470c-bc9d-68906315da3a","SECTION 8.4.6","NarrativeContent_74","<div></div>","Reporting of SAEs","8.4.6"
"4e379088-6972-49a5-bb84-fef7870a2f72","SECTION 8.4.7","NarrativeContent_75","<div></div>","Regulatory Reporting Requirements for SAEs","8.4.7"
"20bf2527-37e0-4b1e-b875-d4f940ac18c5","SECTION 8.4.8","NarrativeContent_76","<div></div>","Serious and Unexpected Adverse Reaction Reporting","8.4.8"
"03786996-5b54-48ca-9dd0-8a535828e80d","SECTION 8.4.9","NarrativeContent_77","<div></div>","Adverse Events of Special Interest","8.4.9"
"b7600019-06da-4f5a-80fb-6a0764f00a67","SECTION 8.4.10","NarrativeContent_78","<div></div>","Disease-related Events or Outcomes Not Qualifying as AEs or SAEs","8.4.10"
"eea6c12a-54dc-49be-bcbb-9ed1d3dfdd84","SECTION 8.5","NarrativeContent_79","<div></div>","Pregnancy and Postpartum Information","8.5"
"0057a05c-bc33-4533-af1e-dbf4d93a5c47","SECTION 8.5.1","NarrativeContent_80","<div></div>","Participants Who Become Pregnant During the Trial","8.5.1"
"3b5c632f-8dd7-4376-aaa7-1f03c902fceb","SECTION 8.5.2","NarrativeContent_81","<div></div>","Participants Whose Partners Become Pregnant","8.5.2"
"bc0f9ce7-d11c-48eb-831e-24e954845957","SECTION 8.6","NarrativeContent_82","<div></div>","Medical Device Product Complaints for Drug/Device Combination Products","8.6"
"22ec2751-f7a2-4754-b2bc-41f63a3dfd64","SECTION 8.6.1","NarrativeContent_83","<div></div>","Definition of Medical Device Product Complaints","8.6.1"
"ab0119ba-6548-4392-99e6-02da94461a88","SECTION 8.6.2","NarrativeContent_84","<div></div>","Recording of Medical Device Product Complaints","8.6.2"
"de38fe2f-2ef9-4657-aed3-e064b8d232bc","SECTION 8.6.3","NarrativeContent_85","<div></div>","Time Period and Frequency for Collecting Medical Device Product Complaints .","8.6.3"
"2013c809-a4fb-4bd8-93a1-1b53653980f6","SECTION 8.6.4","NarrativeContent_86","<div></div>","Follow-Up of Medical Device Product Complaints","8.6.4"
"c17cc84c-0ab3-474f-aea2-72001846ceff","SECTION 8.6.5","NarrativeContent_87","<div></div>","Regulatory Reporting Requirements for Medical Device Product Complaints","8.6.5"
"4e7aadd4-e7f2-4f0b-a2bb-93e1569436a9","SECTION 8.7","NarrativeContent_88","<div></div>","Pharmacokinetics","8.7"
"b7a0e861-92d0-48fa-a7fb-9ae34f9f5302","SECTION 8.8","NarrativeContent_89","<div></div>","Genetics","8.8"
"094d7cfb-e14e-4788-811c-8044eb3a2223","SECTION 8.9","NarrativeContent_90","<div></div>","Biomarkers","8.9"
"fcdb0ced-0ffb-4779-8a34-d5929a93d688","SECTION 8.1","NarrativeContent_91","<div></div>","Immunogenicity Assessments","8.1"
"fd6ec209-eefd-433d-bb61-02b06574cfb9","SECTION 8.1.1","NarrativeContent_92","<div></div>","Medical Resource Utilisation and Health Economics","8.1.1"
"da6e5de5-3fc8-4510-9a6d-0c507d3026b9","SECTION 9","NarrativeContent_93","<div></div>","STATISTICAL CONSIDERATIONS","9"
"ae61763a-928a-43c9-aa5e-b65e2ec19876","SECTION 9.1","NarrativeContent_94","<div></div>","Analysis Sets","9.1"
"075de716-a031-41f6-a54a-590d77e07464","SECTION 9.2","NarrativeContent_95","<div></div>","Analyses Supporting Primary Objective(s)","9.2"
"ae686c73-1849-4076-85a1-259bd8c05df3","SECTION 9.2.1","NarrativeContent_96","<div></div>","Statistical Model, Hypothesis, and Method of Analysis","9.2.1"
"1a9aee5c-28c4-4526-ad64-00e85da03d1a","SECTION 9.2.2","NarrativeContent_97","<div></div>","Handling of Intercurrent Events of Primary Estimand(s)","9.2.2"
"51fb103a-a043-44a5-a6ac-39e12bc744ba","SECTION 9.2.3","NarrativeContent_98","<div></div>","Handling of Missing Data","9.2.3"
"a21cc1e6-39b9-4343-b2e6-31ce6e1d625d","SECTION 9.2.4","NarrativeContent_99","<div></div>","Sensitivity Analysis","9.2.4"
"553580df-23a7-466e-b958-0fdcfde836ac","SECTION 9.2.5","NarrativeContent_100","<div></div>","Supplementary Analysis","9.2.5"
"4636190e-f752-4b8e-8cb9-ab1ae8c0b345","SECTION 9.3","NarrativeContent_101","<div></div>","Analysis Supporting Secondary Objective(s)","9.3"
"cff2ddd5-18d2-4564-a401-1ecc53ac8bfe","SECTION 9.4","NarrativeContent_102","<div></div>","Analysis of Exploratory Objective(s)","9.4"
"e7205f72-e958-4506-8bf5-b49a0d857a96","SECTION 9.5","NarrativeContent_103","<div></div>","Safety Analyses","9.5"
"5bb1b69c-71e8-41b1-8a16-7aa4aa7d10b5","SECTION 9.6","NarrativeContent_104","<div></div>","Other Analyses","9.6"
"7052f778-4f49-4cc3-b00d-11c4e460a738","SECTION 9.7","NarrativeContent_105","<div></div>","Interim Analyses","9.7"
"a42133bc-05fe-42ed-9370-5904a09ea57d","SECTION 9.8","NarrativeContent_106","<div></div>","Sample Size Determination","9.8"
"791d6490-492e-48b7-a854-c5cddd7356ad","SECTION 9.9","NarrativeContent_107","<div></div>","Protocol Deviations","9.9"
"1a686889-893e-4f34-89f7-843b823a8f89","SECTION 10","NarrativeContent_108","<div></div>","GENERAL CONSIDERATIONS: REGULATORY, ETHICAL, AND TRIAL OVERSIGHT","10"
"63cc682c-ff90-4a04-9517-f4ed384bad03","SECTION 10.1","NarrativeContent_109","<div></div>","Regulatory and Ethical Considerations","10.1"
"c393681d-25f0-4317-a017-ce094c6ab2fc","SECTION 10.2","NarrativeContent_110","<div></div>","Committees","10.2"
"484c848a-cc07-495d-b0ee-99eac1bec230","SECTION 10.3","NarrativeContent_111","<div></div>","Informed Consent Process","10.3"
"72d1d68d-21b3-4946-be5a-012855c96b08","SECTION 10.4","NarrativeContent_112","<div></div>","Data Protection","10.4"
"aebd0e66-3990-49d6-bd37-9f1d13d43d63","SECTION 10.5","NarrativeContent_113","<div></div>","Early Site Closure or Trial Termination","10.5"
"87d1ecb5-ae36-4f09-aa9a-9ddcc95ae46c","SECTION 11","NarrativeContent_114","<div></div>","GENERAL CONSIDERATIONS: RISK MANAGEMENT AND QUALITY ASSURANCE","11"
"d4d1e494-d2ae-41d5-bcbc-6b7c247e2536","SECTION 11.1","NarrativeContent_115","<div></div>","Quality Tolerance Limits","11.1"
"b71e9de1-43c9-4e97-a52f-7eb23d779f36","SECTION 11.2","NarrativeContent_116","<div></div>","Data Quality Assurance","11.2"
"10d7026a-eb46-488c-8f42-ec734ef4590e","SECTION 11.3","NarrativeContent_117","<div></div>","Source Data","11.3"
"68eea28f-be7f-4f75-9844-ddaf7bb0b357","SECTION 12","NarrativeContent_118","<div></div>","APPENDIX: ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS - DEFINITIONS, SEVERITY, AND CAUSALITY","12"
"5fa2773b-449e-4901-be04-7d8e6df24d54","SECTION 12.1","NarrativeContent_119","<div></div>","Further Details and Clarifications on the AE Definition","12.1"
"329eb928-5056-402f-9acc-78a7df35eed3","SECTION 12.2","NarrativeContent_120","<div></div>","Further Details and Clarifications on the SAE Definition","12.2"
"5fb37b74-d997-4b20-8d45-da4f0c7a74ed","SECTION 12.3","NarrativeContent_121","<div></div>","Severity","12.3"
"e992ac46-de79-42c3-834e-38c2e8de894f","SECTION 12.4","NarrativeContent_122","<div></div>","Causality","12.4"
"ffc673be-60eb-4006-8545-030c83c9da3b","SECTION 13","NarrativeContent_123","<div></div>","APPENDIX: DEFINITIONS AND SUPPORTING OPERATIONAL DETAILS","13"
"521f3c25-f6df-42a2-9f81-5fc86312af85","SECTION 13.1","NarrativeContent_124","<div></div>","Contraception and Pregnancy Testing","13.1"
"f0792363-3455-4218-a85b-a582971a7860","SECTION 13.1.1","NarrativeContent_125","<div></div>","Definitions Related to Childbearing Potential","13.1.1"
"c0592853-9a86-45c7-bec2-2212aa605e52","SECTION 13.1.2","NarrativeContent_126","<div></div>","Contraception","13.1.2"
"c8f661e6-fa9a-41f5-92f6-1de386996a80","SECTION 13.1.3","NarrativeContent_127","<div></div>","Pregnancy Testing","13.1.3"
"7b75cad6-19ac-40e1-9a2c-8e7c0f6a9e56","SECTION 13.2","NarrativeContent_128","<div></div>","Clinical Laboratory Tests","13.2"
"f2eb09fa-c9ff-4455-a469-cedd968df38f","SECTION 13.3","NarrativeContent_129","<div></div>","Country/Region-Specific Differences","13.3"
"281dfc95-366b-4ece-b711-3a833b28fb75","SECTION 13.4","NarrativeContent_130","<div></div>","Prior Protocol Amendments","13.4"
"1274482b-e193-4f34-829d-ddd7f1523e20","SECTION 14","NarrativeContent_131","<div></div>","APPENDIX: GLOSSARY OF TERMS","14"
"a174be77-a213-4bdc-8fa7-f2392a208893","SECTION 15","NarrativeContent_132","<div></div>","APPENDIX: REFERENCES","15"
